THE PHILIPS INTELLIVUE MP60, MP70, AND MP90 PATIENT MONITORS, RELEASE A.20

K031481 · Philips Medizin Systeme Boblingen GmbH · MHX · May 29, 2003 · Cardiovascular

Device Facts

Record IDK031481
Device NameTHE PHILIPS INTELLIVUE MP60, MP70, AND MP90 PATIENT MONITORS, RELEASE A.20
ApplicantPhilips Medizin Systeme Boblingen GmbH
Product CodeMHX · Cardiovascular
Decision DateMay 29, 2003
DecisionSESE
Submission TypeSpecial
Regulation21 CFR 870.1025
Device ClassClass 2
AttributesPediatric

Intended Use

Indicated for use by health care professionals whenever there is a need for monitoring the physiological parameters of patients. Intended for monitoring, recording and alarming of multiple physiological parameters of adults, pediatrics and neonates in hospital environments. EASI 12-lead ECG is only for use on adult and pediatric patients. ST Segment monitoring is restricted to adult patients only. The transcutaneous gas measurement (tcp02 / tcpCO2) is restricted to neonatal patients only.

Device Story

Philips IntelliVue MP60, MP70, and MP90 are multi-parameter patient monitors used in hospital environments by healthcare professionals. Devices acquire physiological signals (ECG, blood pressure, SpO2, gas analysis, EEG, etc.) via connected sensors/probes. System processes inputs to provide real-time monitoring, recording, and alarming of patient status. Output displayed on integrated screens for clinician review to support clinical decision-making. Modification involves updated software release A.20. Benefits include continuous patient surveillance and timely notification of physiological changes.

Clinical Evidence

Bench testing only. Verification and validation activities included system-level tests, performance tests, and safety testing based on hazard analysis. Pass/Fail criteria were based on predicate device specifications.

Technological Characteristics

Multi-parameter patient monitor system. Includes ECG, blood pressure, oximetry, gas analysis, and EEG modules. Connectivity via network/communication systems. Software-based monitoring and alarming. Class III (arrhythmia detection) and Class II/I components. No specific materials or ASTM standards cited.

Indications for Use

Indicated for monitoring physiological parameters in adult, pediatric, and neonatal patients in hospital environments. EASI 12-lead ECG limited to adults/pediatrics; ST segment monitoring limited to adults; transcutaneous gas measurement limited to neonates.

Regulatory Classification

Identification

The arrhythmia detector and alarm device monitors an electrocardiogram and is designed to produce a visible or audible signal or alarm when atrial or ventricular arrhythmia, such as premature contraction or ventricular fibrillation, occurs.

Special Controls

*Classification.* Class II (special controls). The guidance document entitled “Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm” will serve as the special control. See § 870.1 for the availability of this guidance document.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of the Safe Medical Devices Act of 1990 and 21 C.F.R. §807.92. - 1. The submitter of this premarket notification is: Hauke Schik Philips Medizin Systeme Boeblingen GmbH Hewlett-Packard-Str. 2 D-71034 Boeblingen, Germany Tel: ++49 7031 463-2031 Fax: ++49 7031 463-2442 e-mail: hauke.schik@philips.com This summary was prepared on May 05, 2003. - 2. The names of the devices are the Philips MP60, MP70, and MP90 IntelliVue Patient Monitor. Classification names are as follows: | Device Panel | Classification | ProCode | Description | |------------------------------------------|-----------------|---------|-----------------------------------------------------------------------------| | Circulatory<br>System Devices<br>(12625) | \$870.1025, III | DSI | Detector and alarm, arrhythmia | | | \$870.1025, III | MLD | Monitor, ST Segment with Alarm | | | \$870.1025, III | MHX | Monotor, Physiological, Patient<br>(with arrhythmia detection or<br>alarms) | | | \$870.1100, II | DSJ | Alarm, Blood Pressure | | | \$870.1110, II | DSK | Computer, Blood Pressure | | | \$870.1130, II | DXN | System, Measurement, Blood-<br>Pressure, Non-Invasive | | | \$870.1435, II | DXG | Computer, Diagnostic, Pre-<br>Programmed, Single-Function | | | \$870.1915, II | KRB | Probe, Thermodilution | | | \$870.2060, II | DRQ | Amplifier and Signal<br>Conditioner, Transducer Signal | | | \$870.2300, II | DRT | Monitor, Cardiac (incl.<br>Cardiotachometer & Rate Alarm) | | | \$870.2340, II | DPS | Electrocardiograph | | | \$870.2340, II | MLC | Monitor, ST Segment | | | \$870.2350, II | DRW | Electrocardiograph, Lead<br>Switching Adapter | | | \$870.2370, II | KRC | Tester, Electrode, Surface,<br>Electrocardiograph | | | \$870.2450, II | DXJ | Display, Cathode-Ray Tube,<br>Medical | | | \$870.2600, I | DRJ | System, Signal Isolation | | | \$870.2700, II | DQA | Oximeter | | | \$870.2770, II | DSB | Plethysmograph, Impedance | | | \$870.2800, II | DSH | Recorder, Magnetic tape,<br>Medical | | | \$870.2810, I | DSF | Recorder, Paper Chart | | | \$870.2850, II | DRS | Extravascular Blood Pressure<br>Transducer | | | \$870.2900, I | DSA | Cable, Transducer and<br>Electrode, incl. Patient<br>Connector | {1}------------------------------------------------ | | | MSX | System, Network and<br>Communication, Physiological<br>Monitors | |------------------------------------------------------|----------------|-----|------------------------------------------------------------------------------| | Anesthesiology<br>and Respiratory<br>Therapy (12624) | \$868.1400, II | CCK | Analyzer, Gas, Carbon Dioxide,<br>Gaseous-Phase | | | \$868.1500, II | CBQ | Analyzer, Gas, Enflurane,<br>Gaseous-Phase (Anesthetic<br>Concentration) | | | \$868.1500, II | NHO | Analyzer, Gas, Desflurane,<br>Gaseous-Phase (Anesthetic<br>Concentration)- | | | \$868.1500, II | NHP | Analyzer, Gas, Sevoflurane,<br>Gaseous-Phase (Anesthetic<br>Concentration) | | | \$868.1500, II | NHQ | Analyzer, Gas, Isoflurane,<br>Gaseous-Phase (Anesthetic<br>Concentration) | | | \$868.1620, II | CBS | Analyzer, Gas, Halothane,<br>Gaseous-Phase (Anesthetic<br>Concentration) | | | \$868.1700, II | CBR | Analyzer, Gas, Nitrous Oxide,<br>Gaseous-Phase (Anesthetic<br>Concentration) | | | \$868.1720, II | CCL | Analyzer, Gas, Oxygen, Gaseous-<br>Phase | | | \$868.2375, II | BZQ | Monitor, Breathing Frequency | | | \$868.2480, II | LKD | Monitor, Carbon Dioxide,<br>Cutaneous | | | \$868.2500, II | KLK | Monitor, Oxygen, Cutaneous, for<br>Infant not under Gas Anesthesia | | General Hospital<br>and Personal Use<br>(12520) | \$880.2910, II | FLL | Thermometer, Electronic,<br>Clinical | | Neurological<br>(12513) | \$882.1400, II | GWR | Electroencephalograph | | | \$882.1420, I | GWS | Analyzer, Spectrum,<br>Electroencephalogram Signal | - 3. The new devices are substantially equivalent to previously cleared Philips devices marketed pursuant to K001664, K021778 and 030038. - 4. The modification is updated software of the Philips Medical System MP60, MP70 and MP90 IntelliVue patient monitor devices. - 5. The new devices have the same intended use as the legally marketed predicate devices. When used in the hospital environment, they are intended for the monitoring, recording, and alarming of multiple physiological parameters of adults, pediatrics, and neonates. - 6. The new devices have the same technological characteristics as the legally marketed predicate devices. - 7. Verification, validation, and testing activities establish the performance, functionality, and reliability characteristics of the new device with respect to the {2}------------------------------------------------ K031481 page 3 of 3 Testing involved system level tests, performance predicate. tests, and safety testing from hazard analysis. Pass/Fail criteria were based on the specifications cleared for the predicate device and test results showed substantial equivalence. The results demonstrate that Component Compact Monitor meets all reliability requirements and performance claims. {3}------------------------------------------------ Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus, which is a symbol often associated with healthcare. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES · USA" are arranged in a circular pattern around the caduceus. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 MAY 2 9 2003 Philips Medizin Systeme Boeblingen GmbH c/o Mr. Hauke Schik Sr. Regulatory Affairs Engineer Cardiac and Monitoring Systems Hewlett-Packard Str. 2 Boeblingen Germany D-71034 Re: K031481 Trade Name: The Philips MP60, MP70 and MP90 IntelliVue Patient Monitors Regulation Number: 21 CFR 870.1025 Regulation Name: Arrhythmia detector and alarm Regulatory Class: Class III (three) Product Code: MHX Dated: May 5, 2003 Received: May 12, 2003 Dear Mr. Schik: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {4}------------------------------------------------ Page 2 - Mr. Hauke Schik Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely yours, Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ 031481 Page 1 of 2 510(k) Number (if known): Device Name: The Philips IntelliVue MP60, MP70, and MP90 Patient Monitors, Release A.20. K D3 14 Indications for Use: Indicated for use by health care professionals whenever there is a need for monitoring the physiological parameters of patients. Intended for monitoring, recording and alarming of multiple physiological parameters of adults, pediatrics and neonates in hospital environments. EASI 12-lead ECG is only for use on adult and pediatric patients. ST Segment monitoring is restricted to adult patients only. The transcutaneous gas measurement (tcp02 / tcpCO2) is restricted to neonatal patients only. (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) | Prescription Use | X | OR | Over-The-Counter | |--------------------------|---|----|------------------| | (Per 21 CFR 801.109) | | | | | (Optional Format 1-2-96) | | | | (Division Sign-Off) Division of Cardiovascular Devices | 510(k) Number | K03148/ | |---------------|---------| |---------------|---------| 10
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%